DE1149002B - Process for the preparation of hypertensive salts of N, N-dialkyl-2-ethyl-3, 3-diphenyl-propen- (2) -yl-amines - Google Patents

Process for the preparation of hypertensive salts of N, N-dialkyl-2-ethyl-3, 3-diphenyl-propen- (2) -yl-amines

Info

Publication number
DE1149002B
DE1149002B DEG33376A DEG0033376A DE1149002B DE 1149002 B DE1149002 B DE 1149002B DE G33376 A DEG33376 A DE G33376A DE G0033376 A DEG0033376 A DE G0033376A DE 1149002 B DE1149002 B DE 1149002B
Authority
DE
Germany
Prior art keywords
ethyl
diphenyl
propen
dialkyl
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEG33376A
Other languages
German (de)
Inventor
Dipl-Chem Dr Werner Heinrich
Dipl-Chem Dr Walter Heigel
Dipl-Chem Dr Horst Eissler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BK Giulini Chemie GmbH
Original Assignee
Giulini Gebrueder GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giulini Gebrueder GmbH filed Critical Giulini Gebrueder GmbH
Priority to DEG33376A priority Critical patent/DE1149002B/en
Priority to FR19889A priority patent/FR1395525A/en
Priority to GB39471/62A priority patent/GB960302A/en
Publication of DE1149002B publication Critical patent/DE1149002B/en
Priority to US634430A priority patent/US3489760A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

DEUTSCHESGERMAN

PATENTAMTPATENT OFFICE

G33376TVb/12oG33376TVb / 12o

ANMELDETAG: 19. OKTOBER 1961 REGISTRATION DATE: OCTOBER 19, 1961

BEKANNTMACHUNG DER ANMELDUNG UNDAUSGABEDER AUSLEGESCHRIFT: 22. MAI 1963NOTICE THE REGISTRATION ANDOUTPUTE EDITORIAL: MAY 22, 1963

Es ist bekannt, daß man durch Grignardierung von /9-Aminopropionsäureestern mit Phenylmagnesiumbromid zu S-Hydroxy-S^-diphenyl-propylaminen gelangen kann. Es ist weiterhin bekannt, daß man aus diesen Aminoalkoholen durch Wasserabspaltung die entsprechenden 3,3-Diphenyl-propen-(2)-yl-amine erhält. (D. W. Adamson, J. Chem. Soc. Supplement, 1949, S. 144 ff.).It is known that by Grignardation of / 9-aminopropionic acid esters with phenylmagnesium bromide to S-hydroxy-S ^ -diphenyl-propylamines can get. It is also known that these amino alcohols can be obtained by splitting off water the corresponding 3,3-diphenyl-propen- (2) -yl-amine is obtained. (D. W. Adamson, J. Chem. Soc. Supplement, 1949, pp. 144 ff.).

C6H5 OHC 6 H 5 OH

\l\ l

C-CH-CH2NR2R3 C6H5 RiC-CH-CH 2 NR 2 R 3 C 6 H 5 Ri

C5H5 C 5 H 5

C6H5 C 6 H 5

= C-CH2NR2R3 = C-CH 2 NR 2 R 3

RiRi

Eine Anzahl derartiger Substanzen obiger Formeln, in denen Ri = Wasserstoff oder Methyl, R2 und R3 = Alkyl sind, wurde hergestellt und insbesondere auf ihre spasmolytische Wirkung untersucht.A number of such substances of the above formulas, in which Ri = hydrogen or methyl, R 2 and R 3 = alkyl, were prepared and examined in particular for their spasmolytic effect.

Überraschenderweise hat sich nun gezeigt, daß in den Fällen, in denen die Kohlenstoffkette verzweigt und Ri eine Äthylgruppe darstellt, man neue Substanzen erhält, die andere interessante pharmakologische Eigenschaften besitzen. Man erhält nämlich Substanzen, die eine starke und vor allem langanhaltende Blutdrucksteigerung bewirken.Surprisingly, it has now been shown that in those cases in which the carbon chain is branched and Ri represents an ethyl group, one obtains new substances, the other interesting ones possess pharmacological properties. Namely, you get substances that are strong and strong all cause long-lasting increase in blood pressure.

Die Herstellung von blutdrucksteigernden Salzen von N,N-Dialkyl-2-äthyl-3,3-diphenyl-propen-(2)-ylaminen erfolgt erfindungsgemäß dadurch, daß man entweder in an sich bekannter Weise das 2-Äthyl-3,3-diphenyl-propen-(2)-yl-amin mit Carbonylverbindungen und Ameisensäure umsetzt oder daß man in an sich bekannter Weise aus den N,N-Dialkyl-2-äthyl-3,3-diphenyl-3-hydroxy-propyl-aminen 1 Mol Wasser abspaltet, worauf man die erhaltenen N,N-Dialkyl-2-äthyl-3,3-diphenyl-propen-(2)-yl-amine in üblicher Weise als Salze isoliert.The production of hypertensive salts of N, N-dialkyl-2-ethyl-3,3-diphenyl-propen- (2) -ylamines takes place according to the invention that either in a known manner the 2-ethyl-3,3-diphenyl-propen (2) -yl-amine is reacted with carbonyl compounds and formic acid or in a manner known per se from the N, N-dialkyl-2-ethyl-3,3-diphenyl-3-hydroxypropyl-amines 1 mol of water is split off, whereupon the N, N-dialkyl-2-ethyl-3,3-diphenyl-propen (2) -yl-amines obtained isolated in the usual way as salts.

Es ergibt sich z. B. folgende Blutdrucksteigerung bei der Katze in Urethan-Chloralose-Narkose:It results z. B. The following increase in blood pressure in cats under urethane-chloralose anesthesia:

a) N,N-Dimethyl-2-äthyl-3,3-diphenyl-propen-(2)-yl-amin als Hydrochloric!, Gluconat, Nicotinat oder Methansulfonata) N, N-dimethyl-2-ethyl-3,3-diphenyl-propen- (2) -yl-amine as Hydrochloric !, gluconate, nicotinate or methanesulfonate

1 mg/kg i. v. Blutdrucksteigerung von 15 bis 20 mm Hg, etwa 30 Minuten anhaltend; 1 mg / kg i.v. v. Blood pressure increase of 15 to 20 mm Hg, lasting about 30 minutes;

Verfahren zur Herstellung vonProcess for the production of

blutdrucksteigernden Salzen vonhypertensive salts of

N,N-Dialkyl-2-äthyl-3,3-diphenyl-N, N-dialkyl-2-ethyl-3,3-diphenyl-

propen-(2)-yl-aminenpropen- (2) -yl-amines

Anmelder:Applicant:

Gebrüder Giulini G. m. b. H.,
Ludwigshafen/Rhein, Giulinistr. 2
Giulini brothers G. mb H.,
Ludwigshafen / Rhine, Giulinistr. 2

Dipl.-Chem. Dr. Werner Heinrich,
Dipl.-Chem. Dr. Walter Heigel,
Dipl.-Chem. Dr. Werner Heinrich,
Dipl.-Chem. Dr. Walter Heigel,

Ludwigshafen/Rhein,Ludwigshafen / Rhine,

und Dipl.-Chem. Dr. Horst Eißler,and Dipl.-Chem. Dr. Horst Eißler,

Ludwigshafen/Rhein-Mundenheim,Ludwigshafen / Rhein-Mundenheim,

sind als Erfinder genannt wordenhave been named as inventors

2 mg/kg i. v. Blutdrucksteigerung von 25 bis 40 mm Hg, etwa 1 bis 2 Stunden anhaltend.2 mg / kg i.v. v. Blood pressure increase of 25 to 40 mm Hg, about 1 to 2 hours persistent.

b) N,N-Dipropyl-2-äthyl-3,3-diphenyl-propen-(2)-yl-amin als Hydrochlorid, Gluconat, Nicotinat oder Methansulfonatb) N, N-Dipropyl-2-ethyl-3,3-diphenyl-propen (2) -yl-amine as hydrochloride, gluconate, nicotinate or methanesulfonate

1 mg/kg i. v. Blutdrucksteigerung von 20 bis1 mg / kg i.v. v. Blood pressure increase from 20 to

30 mm Hg, etwa 1 Stunde anhaltend; 30 mm Hg, lasting about 1 hour;

2 mg/kg i. v. Blutdrucksteigerung von 30 bis2 mg / kg i.v. v. Blood pressure increase from 30 to

60 mm Hg, etwa 11^ bis 4 Stunden anhaltend.60 mm Hg, lasting about 1 1 ^ to 4 hours.

Bei erniedrigtem Ausgangsblutdruck ist die blutdrucksteigernde Wirkung stärker und länger anhaltend als bei normalem oder überhöhtem Ausgangsblutdruck.
Unter gleichen Versuchsbedingungen bewirkt z. B.
If the initial blood pressure is reduced, the blood pressure-increasing effect is stronger and longer lasting than if the initial blood pressure is normal or too high.
Under the same test conditions z. B.

das l-(3-Hydroxyphenyl)-l-hydroxy-2-N-äthyl-the l- (3-hydroxyphenyl) -l-hydroxy-2-N-ethyl-

amino-äthan-hydrochlorid bei einer Dosierung von 1 bis 4 mg/kg eine Blutdrucksteigerung von 20 bis 60 mm Hg, die jedoch nur 4 bis 8 Minuten anhält.amino ethane hydrochloride at a dosage of 1 to 4 mg / kg an increase in blood pressure of 20 to 60 mm Hg, but only lasts 4 to 8 minutes.

Entsprechend bewirkt Ephedrin bei einer Dosierung von 1 bis 3 mg/kg eine Blutdrucksteigerung von 20 bis 50 mm Hg, die maximal bis etwa 40 Minuten anhält.Correspondingly, at a dose of 1 to 3 mg / kg, ephedrine increases blood pressure from 20 to 50 mm Hg, which lasts a maximum of about 40 minutes.

309 597/345309 597/345

Beispiel 1example 1

N-Methyl-N-cyclohexyl-2-äthyl-3,3-diphenylpropen-(2)-yl-amin-hydrochlorid N-methyl-N-cyclohexyl-2-ethyl-3,3-diphenylpropene- (2) -ylamine hydrochloride

6,4g N-Cyclohexyl-2-äthyl-3,3-diphenyl-propen-(2)-yl-amin werden unter Kühlung mit 2,3 g Ameisensäure und 0,25 ml Wasser versetzt. Weiter werden 1,9 ml wäßrige Formaldehydlösung zugesetzt (35%ig) und der Ansatz 15 Stunden auf 1100C erwärmt. Nach dem Abkühlen wird mit 9 ml konzentrierter Salzsäure angesäuert und im Vakuum zur Trockene destilliert. Der Rückstand wird mit verdünnter Natronlauge versetzt, ausgeäthert und der mit Natriumsulfat getrocknete Ätherteil abdestilliert. Der Rückstand wird in methanolischer Salzsäure 1S gelöst und durch Zugabe von Äther das N-Methyl-N - cyclohexyl - 2 - äthyl - 3,3 - diphenyl - propen - (2) - ylamin-hydrochlorid kristallin erhalten.6.4 g of N-cyclohexyl-2-ethyl-3,3-diphenyl-propen (2) -yl-amine are mixed with 2.3 g of formic acid and 0.25 ml of water while cooling. 1.9 ml of aqueous formaldehyde solution (35%) are also added and the batch is heated to 110 ° C. for 15 hours. After cooling, it is acidified with 9 ml of concentrated hydrochloric acid and distilled to dryness in vacuo. The residue is mixed with dilute sodium hydroxide solution, extracted with ether and the ether part, dried with sodium sulfate, is distilled off. The residue is dissolved in 1 S methanolic hydrochloric acid and, by adding ether, the N-methyl-N-cyclohexyl-2-ethyl-3,3-diphenyl-propen-(2) -ylamine hydrochloride is obtained in crystalline form.

Fp. 170 bis 1730C. Ausbeute: 80% der Theorie.Mp. 170 to 173 ° C. Yield: 80% of theory.

Beispiel 2Example 2

N,N-Dipropyl-2-äthyl-3,3-diphenyl-propen-(2)-yl-N, N-Dipropyl-2-ethyl-3,3-diphenyl-propen- (2) -yl-

amin-hydrochloridamine hydrochloride

4,7 g 2-Äthyl-3,3-diphenyl-propen-(2)-yl-amin werden unter Kühlung zu einem Gemisch aus 4,6 g Ameisensäure und 0,5 ml Wasser gegeben. Man fügt 3,2 ml Propionaldehyd hinzu und erhitzt den Ansatz 15 Stunden auf 110°C. Nach dem Abkühlen werden 18 ml konzentrierte Salzsäure dazugegeben und die überschüssige Ameisensäure sowie der überschüssige Propionaldehyd im Vakuum abdestilliert. Der Rückstand wird alkalisch gemacht, ausgeäthert und der mit Natriumsulfat getrocknete, abgetrennte Ätherteil abdestilliert. Der Rückstand wird in methanohscher Salzsäure gelöst und durch Zugabe von Äther das N,N-Dipropyl-2-äthylpropen-(2)-yl-amin-hydrochlorid erhalten.4.7 g of 2-ethyl-3,3-diphenyl-propen- (2) -yl-amine are cooled to give a mixture of 4.6 g Formic acid and 0.5 ml of water were added. 3.2 ml of propionaldehyde are added and the batch is heated 15 hours at 110 ° C. After cooling, 18 ml of concentrated hydrochloric acid are added and the Excess formic acid and the excess propionaldehyde are distilled off in vacuo. The residue is made alkaline, etherified and the ether part, dried with sodium sulphate, is separated distilled off. The residue is dissolved in methane hydrochloric acid and added obtained from ether the N, N-dipropyl-2-äthylpropen- (2) -yl-amine hydrochloride.

Fp. 221 bis 222° C.Mp. 221 to 222 ° C.

Beispiel 3Example 3

N,N-Dimethyl-2-äthyl-3,3-diphenyl-propen-(2)-ylamin-hydrochlorid N, N-dimethyl-2-ethyl-3,3-diphenyl-propen (2) -ylamine hydrochloride

14,1 g 2-Äthyl-3,3-diphenyl-propen-(2)-yl-amin werden unter Kühlung zu einem Gemisch von 13,8 g Ameisensäure und 1,5 ml Wasser gegeben. Dem Reaktionsgemisch werden 11,4 ml 35°/oige wäßrige Formaldehydlösung zugesetzt und das Ganze anschließend 15 Stunden auf 1100C erhitzt. Nach dem Abkühlen wird mit 54 ml konzentrierter Salzsäure angesäuert und die überschüssige Ameisensäure-Formalin-Lösung im Vakuum auf dem Wasserbad abdestilliert. Der Rückstand wird mit Natronlauge alkalisch gemacht, ausgeäthert, der abgetrennte Ätherteil mit Natriumsulfat getrocknet und dann abdestilliert. Es verbleibt ein Öl, das in methanolischer Salzsäure gelöst wird. Durch Zugabe von Äther zur Lösung kristallisiert das Hydrochlorid des N,N-Dimethyl-2-äthyl-3,3-diphenyl-propen-(2)-ylamin aus.14.1 g of 2-ethyl-3,3-diphenyl-propen- (2) -yl-amine are added with cooling to a mixture of 13.8 g of formic acid and 1.5 ml of water. To the reaction mixture are added 11.4 ml of 35 ° / o aqueous formaldehyde solution and the whole was then heated for 15 hours 110 0 C. After cooling, it is acidified with 54 ml of concentrated hydrochloric acid and the excess formic acid-formalin solution is distilled off in vacuo on a water bath. The residue is made alkaline with sodium hydroxide solution, extracted with ether, the separated ether part is dried with sodium sulfate and then distilled off. An oil remains which is dissolved in methanolic hydrochloric acid. By adding ether to the solution, the hydrochloride of N, N-dimethyl-2-ethyl-3,3-diphenyl-propen (2) -ylamine crystallizes out.

Fp. 198 bis 2000C. Ausbeute: 84% der Theorie.Mp. 198 to 200 ° C. Yield: 84% of theory.

Claims (1)

PATENTANSPRUCH:PATENT CLAIM: Verfahren zur Herstellung von blutdrucksteigernden Salzen von N,N-Dialkyl-2-äthyl-3,3-diphenyl-propen-(2)-yl-aminen, dadurch gekennzeichnet, daß man entweder in an sich bekannter Weise das 2-Äthyl-3,3-diphenyl-propen-(2)-yl-amin mit Carbonylverbindungen und Ameisensäure umsetzt oder daß man in an sich bekannter Weise aus den N,N-Dialkyl-2-äthyl-3,3-diphenyl-3-hydroxy-propyl-aminen 1 Mol Wasser abspaltet, worauf man die erhaltenen N,N-Dialkyl-2-äthyl-3,3-diphenyl-propen-(2)-ylamine in üblicher Weise als Salze isoliert.Process for the preparation of hypotensive salts of N, N-dialkyl-2-ethyl-3,3-diphenyl-propen (2) -yl-amines, characterized in that either the 2-ethyl-3 , 3-diphenyl-propen- (2) -yl-amine is reacted with carbonyl compounds and formic acid or in a manner known per se from the N, N-dialkyl-2-ethyl-3,3-diphenyl-3-hydroxypropyl -amines split off 1 mol of water, whereupon the N, N-dialkyl-2-ethyl-3,3-diphenyl-propen (2) -ylamines obtained are isolated as salts in the customary manner. In Betracht gezogene Druckschriften:
Deutsche Auslegeschriften Nr. 1051281,1104499; schweizerische Patentschrift Nr. 294 173.
Considered publications:
German Auslegeschriften No. 1051281, 1104499; Swiss Patent No. 294 173.
©309 597/345 5.65© 309 597/345 5.65
DEG33376A 1961-10-19 1961-10-19 Process for the preparation of hypertensive salts of N, N-dialkyl-2-ethyl-3, 3-diphenyl-propen- (2) -yl-amines Pending DE1149002B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DEG33376A DE1149002B (en) 1961-10-19 1961-10-19 Process for the preparation of hypertensive salts of N, N-dialkyl-2-ethyl-3, 3-diphenyl-propen- (2) -yl-amines
FR19889A FR1395525A (en) 1961-10-19 1962-10-04 Manufacturing process of nu, nu-dialkoyl-2-ethyl-3, 3-diphenylpropene- (2) -yl-amnes
GB39471/62A GB960302A (en) 1961-10-19 1962-10-18 Alkenylamines
US634430A US3489760A (en) 1961-10-19 1967-04-24 N,n - methyl cyclohexyl - 2 - ethyl - 3,3 - diphenyl - propene - (2) - yl-amine and the salts thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEG33376A DE1149002B (en) 1961-10-19 1961-10-19 Process for the preparation of hypertensive salts of N, N-dialkyl-2-ethyl-3, 3-diphenyl-propen- (2) -yl-amines

Publications (1)

Publication Number Publication Date
DE1149002B true DE1149002B (en) 1963-05-22

Family

ID=7124680

Family Applications (1)

Application Number Title Priority Date Filing Date
DEG33376A Pending DE1149002B (en) 1961-10-19 1961-10-19 Process for the preparation of hypertensive salts of N, N-dialkyl-2-ethyl-3, 3-diphenyl-propen- (2) -yl-amines

Country Status (4)

Country Link
US (1) US3489760A (en)
DE (1) DE1149002B (en)
FR (1) FR1395525A (en)
GB (1) GB960302A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422203A (en) * 1966-02-24 1969-01-14 Geistlich Ed Sohne Ag Fur Chem Treatment of depression with diphenyl prop-2-enylamine derivatives
EP0864559A1 (en) * 1997-03-14 1998-09-16 Grünenthal GmbH Substituted amino compounds and their use as analgesic active substances

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH294173A (en) * 1950-10-09 1953-10-31 Sharp & Dohme Inc Process for the preparation of a quaternary ammonium compound.
DE1051281B (en) * 1955-07-05 1959-02-26 Bayer Ag Process for the preparation of derivatives of 1-aryl-3-aminopropan-1-ols
DE1104499B (en) * 1957-02-05 1961-04-13 Sterling Drug Inc Process for the preparation of new amino-substituted triphenylethylene compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA525752A (en) * 1956-06-05 V. Petersen Poul Antispasmodic unsaturated tertiary amines
GB624117A (en) * 1946-12-07 1949-05-27 Wellcome Found Improvements in and relating to the preparation of substituted allylamines and propylamines
GB627139A (en) * 1947-05-28 1949-07-29 Wellcome Found Improvements in and relating to the preparation of quaternary ammonium salts of substituted propanolamines, allylamines and propylamines
GB993525A (en) * 1961-05-19 1965-05-26 Smith Kline French Lab Substituted propanolamines and process for preparing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH294173A (en) * 1950-10-09 1953-10-31 Sharp & Dohme Inc Process for the preparation of a quaternary ammonium compound.
DE1051281B (en) * 1955-07-05 1959-02-26 Bayer Ag Process for the preparation of derivatives of 1-aryl-3-aminopropan-1-ols
DE1104499B (en) * 1957-02-05 1961-04-13 Sterling Drug Inc Process for the preparation of new amino-substituted triphenylethylene compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422203A (en) * 1966-02-24 1969-01-14 Geistlich Ed Sohne Ag Fur Chem Treatment of depression with diphenyl prop-2-enylamine derivatives
EP0864559A1 (en) * 1997-03-14 1998-09-16 Grünenthal GmbH Substituted amino compounds and their use as analgesic active substances
US6022895A (en) * 1997-03-14 2000-02-08 Gruenenthal Gmbh Substituted amino compounds and their use as substances having an analgesic effect

Also Published As

Publication number Publication date
US3489760A (en) 1970-01-13
FR1395525A (en) 1965-04-16
GB960302A (en) 1964-06-10

Similar Documents

Publication Publication Date Title
EP0280781B1 (en) Process for the preparation of n-alkyl-n'-methyl-cyclic ureas, especially n,n'-dimethylcyclic ureas
DE1170417B (en) Process for the production of a diphenyl-butylamine with the effect of expanding the coronary vessels
DE1695780A1 (en) Process for the preparation of new N-alkyl-3,1-benzoxain-2-ones
DE2431192C2 (en) O, O-diethylS- [6-chloro-1,3-benzoxazolon-3-yl-methyl] dithiophosphate
DE3328636A1 (en) Xanthine derivatives, processes for their production and their use
DE1149002B (en) Process for the preparation of hypertensive salts of N, N-dialkyl-2-ethyl-3, 3-diphenyl-propen- (2) -yl-amines
DE2144077C3 (en) New Hydroxyäthylaminoalkylpiperazines and processes for their preparation
DE1201338B (en) Process for the preparation of analeptically active N-substituted aminobicyclo-heptane derivatives or of their acid addition salts and quaternary ammonium compounds
DE872947C (en) Process for the production of basic ethers, thioether and their salts
DE1122514B (en) Process for the preparation of hypertensive 2-AEthyl-3,3-diphenyl-propen- (2) -yl-amine
EP0128437B1 (en) Nortropine derivative, process for its preparation and its use
DE961166C (en) Process for the preparation of therapeutically effective substituted 2, 6, 6-trimethylcyclohexen- (1) -yl- (1) -propyl- or -butylamines or their salts and quaternary ammonium compounds
DE699250C (en) Process for the production of decals of ª ‰ - (m-oxyphenyl) -isopropylamine
DE653073C (en) Process for the preparation of alkylaminoalkyl ethers of apoquinine
AT214930B (en) Process for the preparation of new thioxanthene derivatives
DE855119C (en) Process for the preparation of salts of the esters from N-substituted aminoalkanols and substituted or unsubstituted p-aminobenzoic acid
DE1126376B (en) Process for the preparation of blood pressure-increasing N-monoalkylated 2-AEthyl-3, 3-diphenyl-propen- (2) -yl-amines
DE1301999B (en) Process for the production of delta 4, 16-pregnadien-20-ol-3-one
DE2000299A1 (en) Meta-toluic acid derivatives and process for their preparation
DE1206427B (en) Process for the preparation of blood pressure-increasing 2-alkyl-3, 3-diphenylpropene- (2) -ylamines
DE2323150C3 (en) Process for the purification of hexetidine by salt formation
DE1593825C (en) Amino alcohols, their acid addition salts and process for their preparation
DE1668964C3 (en) 1- (2,3,5-Trimethyl-4-hydroxyphenoxy) -3-amino-2-propanol derivatives and processes for their preparation
AT252901B (en) Process for the preparation of the new N- (1-phenylisopropyl) -N-methyl-propynylamine
AT226684B (en) Process for the production of new amino alcohols and their salts